6 May 2021 07:00
e-therapeutics plc
("e-therapeutics" or the "Company")
Notification of Full Year Results Date
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), will announce its full year results for the year ended 31 January 2021 on Thursday 13 May 2021.
e-therapeutics plc | |
Ali Mortazavi, CEO | Tel: +44 (0)1993 883 125 |
Karl Keegan, CFO | www.etherapeutics.co.uk |
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker | |
Matthew Johnson/Caroline Rowe (Corporate Finance) | |
Vadim Alexandre/Rob Rees (Corporate Broking) | |
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.